TOKYO--(EON: Enhanced Online News)--Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President: Yoshihiro Arai, hereinafter “Solasia”) announced today that Solasia and Meiji Seika Pharma Co. Ltd., (Headquarters: Tokyo, Japan, President: Daikichiro Kobayashi, hereinafter “Meiji”) have entered into a license and distribution agreement for the commercialization of episil® (SP-03) in Japan.
Under the terms of this agreement, Solasia will target to obtain approval for episil® for local treatment of pain associated with oral mucositis (OM) in Japan and thereafter Meiji will commercialize, distribute and promote episil®. In consideration of the license granted to Meiji, Solasia will receive upfront and milestone payments, as well as tiered royalties.
Solasia has obtained an exclusive license to develop and commercialize episil® in Japan and China from Camurus AB (“Camurus”) (STO: CAMX). In 2016, Solasia filed for New Medical Device Application for episil® (SP-03) in Japan and China.
episil® oral liquid represents a unique and innovative concept for local treatment of pain associated with oral mucositis (OM). Having been developed using the award-winning* Camurus proprietary technology FluidCrystal®, episil® is administered as lipid-based liquid that spreads on the intraoral mucosal surfaces and transforms to strongly bioadhesive film, which physically protects the sensitized and sore mucosa of the oral cavity. episil® has clinically demonstrated to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours. episil® oral liquid is the only product for OM that is supplied as a ready-to-use, pocket-sized device helping patients maintain their quality of life while undergoing cancer therapy. episil® was first launched in Europe in 2009 and is today commercially available in a number of countries, including the U.S. where it was launched by key global pharmaceutical players. episil® oral liquid is a medical device class 1 in Europe and a 510(k) registered medical device in the U.S.
*FluidCrystal® was awarded the “Best innovation in formulation” prize at the CPhI Worldwide in 2013
About Meiji Seika Pharma Co., Ltd.: - Ethical Pharmaceuticals Business:
As a “Specialty and Generic Pharmaceuticals Company”, Meiji runs its pharmaceutical business in the three main fields, infectious disease and central nervous system disorders, and generic drugs. Meiji strives to respond to diversified medical needs and contributes to the well-being of people worldwide. For details, please visit its corporate website:
Solasia was formed in November 2006 to address unmet needs for important new Western oncology therapies and supportive care products throughout Asia. The company’s mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. To date, Solasia has raised approximately $80 million in venture financing. Additional information is available at http://www.solasia.co.jp/en/